TY  - JOUR
AU  - Liu, H.
AU  - Funke, S. A.
AU  - Willbold, D.
TI  - Transport of Alzheimer disease amyloid-beta-binding D-amino acid peptides across an in vitro blood-brain barrier model
JO  - Rejuvenation research
VL  - 13
SN  - 1549-1684
CY  - Larchmont, NY
PB  - Liebert
M1  - PreJuSER-9878
PY  - 2010
N1  - Record converted from VDB: 12.11.2012
AB  - Previously, two D-enantiomeric amino acid peptides, D1 and D3, which specifically bind to the amyloid-beta peptide Abeta(1-42), were identified by phage display selection. To assess the diagnostic and therapeutic potentials of D1 and D3 for the diagnosis and treatment of Alzheimer disease, the blood-brain barrier transport of these D-peptides was quantitatively evaluated in vitro. Our results showed that the apical-to-basolateral transport of D3 was more efficient than that of D1. An active efflux transport mechanism seems to oppose the transport of D1, whereas D3 is likely to be transported through the blood-brain barrier via an adsorptive-mediated transcytosis mechanism.
KW  - Alzheimer Disease: metabolism
KW  - Amyloid beta-Peptides: chemistry
KW  - Amyloid beta-Peptides: metabolism
KW  - Animals
KW  - Blood-Brain Barrier: metabolism
KW  - Cells, Cultured
KW  - Dose-Response Relationship, Drug
KW  - Models, Theoretical
KW  - Oligopeptides: metabolism
KW  - Oligopeptides: pharmacokinetics
KW  - Peptide Fragments: metabolism
KW  - Peptide Fragments: pharmacokinetics
KW  - Protein Binding
KW  - Protein Transport
KW  - Rats
KW  - Validation Studies as Topic
KW  - Verapamil: pharmacokinetics
KW  - Amyloid beta-Peptides (NLM Chemicals)
KW  - D1 peptide (NLM Chemicals)
KW  - D3 peptide (NLM Chemicals)
KW  - Oligopeptides (NLM Chemicals)
KW  - Peptide Fragments (NLM Chemicals)
KW  - Verapamil (NLM Chemicals)
KW  - J (WoSType)
LB  - PUB:(DE-HGF)16
C6  - pmid:19954305
UR  - <Go to ISI:>//WOS:000277602200019
DO  - DOI:10.1089/rej.2009.0926
UR  - https://juser.fz-juelich.de/record/9878
ER  -